178 related articles for article (PubMed ID: 24601050)
1. Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Tabatabaie A; Karimi Zarchi M; Dehghani-Tafti M; Miratashi-Yazdi A; Teimoori S; Dehghani A
Eur J Gynaecol Oncol; 2013; 34(6):552-5. PubMed ID: 24601050
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
Karimi-Zarchi M; Dehghani-Firoozabadi R; Tabatabaie A; Dehghani-Firoozabadi Z; Teimoori S; Chiti Z; Miratashi-Yazdi A; Dehghani A
Clin Exp Obstet Gynecol; 2013; 40(3):421-4. PubMed ID: 24283179
[TBL] [Abstract][Full Text] [Related]
3. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
Emarh M
Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial.
Moradan S; Nikkhah N; Mirmohammadkhanai M
Adv Ther; 2017 May; 34(5):1211-1220. PubMed ID: 28353144
[TBL] [Abstract][Full Text] [Related]
5. Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice.
Lara AC; Cândido EB; Vidigal PV; Rocha AL; Carvalho-Macedo AC; Carneiro MM; Silva-Filho AL
Acta Cir Bras; 2016 Apr; 31(4):286-93. PubMed ID: 27168542
[TBL] [Abstract][Full Text] [Related]
6. Letrozole as primary therapy for endometrial hyperplasia in young women.
Li HZ; Chen XN; Qiao J
Int J Gynaecol Obstet; 2008 Jan; 100(1):10-2. PubMed ID: 17889878
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
8. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
9. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Pink D; Lindner T; Mrozek A; Kretzschmar A; Thuss-Patience PC; Dörken B; Reichardt P
Gynecol Oncol; 2006 Jun; 101(3):464-9. PubMed ID: 16368128
[TBL] [Abstract][Full Text] [Related]
10. Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Erdenebaatar C; Yamaguchi M; Saito F; Monsur M; Honda R; Tashiro H; Ohba T; Katabuchi H
Int J Gynecol Cancer; 2018 Mar; 28(3):539-544. PubMed ID: 29369118
[TBL] [Abstract][Full Text] [Related]
11. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
12. Curative Polyendocrine Therapy in a 21-year-Old Patient with Endometrial Carcinoma: Case Report and Review of the Literature.
Schäffler H; Dimpfl M; Schochter F; Janni W; de Gregorio N
Oncol Res Treat; 2023; 46(7-8):330-335. PubMed ID: 37364543
[TBL] [Abstract][Full Text] [Related]
13. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the effects and safety of dydrogesterone and medroxyprogesterone acetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study].
Lou YC; Zhou S; Liao JB; Shao WY; Hu YY; Ning CC; Wang Q; Gulinazi Y; Yang BY; Cheng YL; Wu PF; Zhu Q; Zhou XR; Shan WW; Chen XJ
Zhonghua Fu Chan Ke Za Zhi; 2023 Jul; 58(7):526-535. PubMed ID: 37474326
[No Abstract] [Full Text] [Related]
16. Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia.
Takeda A; Yamamoto Y; Tamura K; Aoki H; Noguchi H; Minato S; Kamada S; Arakaki R; Kaji T; Iwasa T
J Obstet Gynaecol Res; 2024 Apr; 50(4):633-638. PubMed ID: 38154145
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-Releasing Hormone Analog Combined with Depot Medroxyprogesterone Acetate in the Management of Endometrial Hyperplasia A Prospective Randomized Clinical Study.
Demir Karakilic I; Karabacak O; Karabacak N; Guler I; Korucuoglu U
J Reprod Med; 2016 Aug; 61(7-8):361-367. PubMed ID: 30408383
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
20. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
